Save time and jump to the most important pieces.
- Fourth-quarter revenue of $0.73 million, up 64% year-over-year – - Full-year revenue of $3.11 million, up 148% year-over-year – - As of June 30, 2024, the Company had $6.30 million in cash - NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, announced its financial results for the fiscal fourth quarter and full-year ended June 30, 2024, and provided a business update. Fiscal fourth quarter revenue totalled $0.73 million, an increase of 64% compared to the same period the prior year, and full-year revenue totalled $3.11 million,
Year-over-year revenue increased 80% for the fiscal third quarter and 193% for the nine months ended March 31, 2024 Cash and cash equivalents as of March 31, 2024, was $9.40 million Commenced FDA 510(k) clinical studies plan with Cliantha Research and remains on track for planned submission by the end of 2024 and planned entry into the US in 2025 Secured 26 new customer accounts throughout the quarter, representing a combined headcount of approximately 16,779 employees NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions,
- Combined full-year revenue and government support income increased 355% year-over-year - - Received guidance from U.S. FDA on a regulatory pathway for its Intelligent Fingerprinting Drug Screening Cartridge - - Granted 13th patent following award of U.K. patent relating to DSR-Plus Cartridge Reader - - Recently secured 8 new customers just two months into product launch in Australia - NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("Intelligent Bio Solutions," "INBS" or the "Company") (NASDAQ:INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for its fiscal fourth quarter
NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will present at the upcoming Noble Capital Markets' 20th Annual Emerging Growth Equity Conference on December 3-4, 2024, in Boca Raton, FL. Noble Capital Markets' 20th Annual Emerging Growth Equity ConferenceDates: December 3-4, 2024Location: Florida Atlantic University, Boca Raton, FLPresentation Day and Time: Wednesday, December 4, 2024, at 2:00 p.m. ET Presentation Location: Presentation Room 3 A link to the recording of the presentation
PK Study Successfully Demonstrates that Fingerprint Sweat Provides Reliable Sample for Drug Detection FDA 510(k) Clearance Would Enable the Introduction of INBS' Technology to the US in 2025 NEW YORK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced strong initial results from its Pharmacokinetic (PK) study required for an FDA 510(k) submission. The data from the PK study shows that fingerprint sweat mimics the rate and extent of codeine in blood and saliva. The study successfully demonstrated that fingerprint sweat provides
NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced a strategic partnership with B2i Digital to launch an investor-focused marketing campaign. B2i Digital will employ advanced digital marketing strategies to raise awareness of INBS' patented drug screening technology, which offers a fast, non-invasive, and efficient alternative to traditional drug tests. "Intelligent Bio Solutions has developed a groundbreaking system that addresses a critical need in industries requiring quick and reliable drug screening," said David S
SC 13G/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)
SC 13G - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)
8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)
8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)
8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)
4 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)
4 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)
3 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)